Jack Nielsen
Director/Miembro de la Junta en HARMONY BIOSCIENCES HOLDINGS, INC. .
Fortuna: - $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Geoffrey Harris | M | - |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | - |
John Butler | M | 59 | 11 años | |
Michael Clayman | M | 72 |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | 10 años |
Richard McGaughy | M | 52 | 12 años | |
Edgar Engleman | M | 78 |
Vivo Co-Invest (S) LP
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 28 años |
Peter Silverman | M | 46 | 7 años | |
Jaume Pons | M | 58 |
Alx Oncology Ltd.
Alx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Alx Oncology Ltd. operates as biotechnology company developing immuno-oncology therapies for cancer. The company was founded by Kipp Weiskopf and Jaume Pons in 2015 and is headquartered in Ireland, Dublin. | 9 años |
Jeffrey Dayno | M | 66 | 7 años | |
Lars Fruergaard Jorgensen | M | 58 | 33 años | |
Jeffrey Dierks | M | 52 |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | 7 años |
Juan Sabater | M | 59 |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | 7 años |
Jason Lettmann | M | 46 | 4 años | |
Anand Mehra | M | 48 | 9 años | |
Antonio Gracias | M | 53 |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | 7 años |
Gary Sender | M | 62 |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | 4 años |
Jeffrey Aronin | M | 56 |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | 7 años |
K. Hirth | M | 72 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 6 años |
Andreas Wicki | M | 64 |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | 7 años |
Sandeep Laumas | M | 56 | 4 años | |
Frank Kung | M | 75 |
Vivo Co-Invest (S) LP
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 28 años |
Gregory Perry | M | 63 | 8 años | |
Eric L. Motley | M | 51 |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | 2 años |
Sandipkumar S. Kapadia | M | 54 | 3 años | |
Gwendolyn Binder-Scholl | M | 49 | 4 años | |
Linda Szyper | F | 58 | 3 años | |
Marc Wilson | M | 44 | 6 años | |
Rekha Hemrajani | F | 54 | 4 años | |
Stephanie Okey | F | 64 | 5 años | |
Brian Szymczak | M | 51 | 10 años | |
Nathan Dau | M | - |
MacuLogix, Inc.
MacuLogix, Inc. Medical/Nursing ServicesHealth Services MacuLogix, Inc. engages in the early detection and tracking of retinal diseases. Its AdaptDx is the first practical measurement tool for dark adaptation which provides doctors with an easy-to-use functional test similar to routine perimetry testing for glaucoma. The company also provides macular degeneration services. The company was founded by John G. Edwards and Gregory R. Jackson in 2004 and is headquartered in Harrisburg, PA.
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 5 años |
Jordyn Tarazi | F | - | - | |
Weston Nichols | M | 39 | 6 años | |
Sushmita M. Chanda | M | 58 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 14 años |
Katherine Stultz | F | 50 |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | 2 años |
Ulrich Christian | M | - | 3 años | |
Sharon Goldbach | F | - | - | |
Brian Burkavage | M | - | 3 años | |
Robert Hawkins | M | 69 | 4 años | |
Bridget Martell | M | 58 | 3 años | |
Kumar Budur | M | 53 | - | |
Barry Templin | M | - | 8 años | |
Amy Sullivan | F | 54 | 2 años | |
R. Graf | M | 59 | 4 años | |
Neil Gibson | M | 67 | 4 años | |
David Smith | M | 64 | 2 años | |
Alan Krasner | M | 60 | 6 años | |
Carole Nüchterlein | F | 62 | 6 años | |
Matthew Fust | M | 59 | 6 años | |
Jim Scopa | M | 65 | 3 años | |
Devin Smith | M | 56 | 1 años | |
Peter Anastasiou | M | 53 | 1 años | |
Karsten Munk Knudsen | M | 53 | 25 años | |
Michel Dahan | M | 45 | 11 años | |
Scott A. Beardsley | M | 56 |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 12 años |
Mahendra Shah | M | 79 |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 14 años |
Henrik Ehlers Wulff | M | 54 | 25 años | |
Nicole Hadas | F | 51 | 11 años | |
Shelly Pinto | F | 48 | 3 años | |
Vera Yang | F | - |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 2 años |
Jack Nielsen | M | - |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | - |
Jason Wang | M | - |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 3 años |
Jane Gong | F | - |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 3 años |
Pierre You | M | - |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 3 años |
Chris Byrd | M | - | 2 años | |
Camilla Sylvest | F | 52 | 28 años | |
Wei Bian | M | - |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 5 años |
Camille Samuels | F | 52 |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | - |
Muhammad Al-Hajj | M | 53 | 3 años | |
Diane McDowell | F | - | 3 años | |
Hong Bo Lu | M | 53 |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 4 años |
Ronele McCurdy | F | - |
ProteinSimple
ProteinSimple Medical SpecialtiesHealth Technology ProteinSimple engages in the proprietary systems and consumables for protein analysis. Its products include simple plex, ice, simple western, micro-flow imaging, and single-cell western. The company was founded by Linda Cahill, Nancy Allbritton, Christopher Sims, Scott Lockard, and Jim Schlater in December 2000 and is headquartered in San Jose, CA. | 13 años |
Mike Gutteridge | M | - | 8 años | |
Jessica Li | F | - |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California. | 4 años |
Heidi Hunter | F | 65 | 1 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
John Jacobs | M | 57 |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | 6 años |
Stefanie Cavanaugh | F | 58 | 7 años | |
Peter Moldt | M | 65 |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark.
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | 15 años |
Robert A. Shalwitz | M | 69 | 7 años | |
Lawrence Blatt | M | 62 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 6 años |
Joseph H. Gardner | M | 68 | 6 años | |
Leonid Beigelman | M | 66 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 12 años |
Manmeet Singh Soni | M | 46 | 4 años | |
William McClellan | M | 64 | 9 años | |
Martin Edwards | M | 68 |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets.
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | 20 años |
Robert Repella | M | 65 |
Harmony Biosciences LLC
Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | - |
John Fry | M | - |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 12 años |
Jason Amello | M | 55 | 7 años | |
Kim Lennart Dueholm | M | 61 |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | 16 años |
Vineet R. Jindal | M | - | 5 años | |
Jakob Riis | M | 58 | 21 años | |
Sumita Ray | F | 50 | 1 años | |
John M. Rice | M | 74 | 7 años | |
Graham Walmsley | M | 37 | 1 años | |
K. Newton | M | 61 | 7 años | |
Mason W. Freeman | M | 73 | 4 años | |
Claus Asbjørn Andersson | M | 56 | 6 años | |
Jesper Brandgaard | M | 60 | 20 años | |
Richard Meelia | M | 75 | 7 años | |
Harry Penner | M | 78 | 8 años | |
Carsten Hellmann | M | 60 | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 80 | 80.00% |
Dinamarca | 19 | 19.00% |
Países Bajos | 3 | 3.00% |
Suiza | 1 | 1.00% |
Irlanda | 1 | 1.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Jack Nielsen
- Red Personal